EXEL insider ownership: who sold, why, and what they still hold

What stands out

Eight insiders sold $34.4M with no disclosed plan: Dana Aftab ($7.7M), Patrick Haley ($7.6M) and Julie Smith ($4.7M), plus 5 more. The filings don't state a reason.Dana Aftab: largest such sale, May 26, 2026 · Patrick Haley: largest such sale, Feb 17, 2026 · Julie Smith: largest such sale, Feb 18, 2026

David Johnson bought 28K shares for $1.2M, first on Nov 25, 2025.Purchase, Nov 25, 2025

Tax withholding outweighed market sales: the company withheld $49.5M of officers' and directors' shares for taxes, against $42.2M sold on the open market. The largest was Michael Morrissey ($34.4M withheld).Largest withholding, Feb 13, 2026

A share of stake is shown for 0 of the 12 officers and directors who sold. 17 are left out

Left out: Michael Morrissey, David Johnson, Stelios Papadopoulos, Christopher Senner, Dana Aftab, Jeffrey Hessekiel, Amy Peterson, Patrick Haley, Jack Wyszomierski, George Poste, Maria Freire, Brenda Hefti, Bob Oliver, Tomas Heyman, Mary Beckerle, Sue Eckhardt and Julie Smith (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Dana Aftab

EVP, Research and Development

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.7MNo plan disclosed

Patrick Haley

EVP, Commercial

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$7.6MNo plan disclosed

Julie Smith

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.7MNo plan disclosed

Jack Wyszomierski

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.6MDisclosed plan

Christopher Senner

EVP and CFO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.6MNo plan disclosed

All 12 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Aug 10, 2026Mary Beckerle sold 9.8K shares ($527K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Mary Beckerle Director	9,812	$53.66	n/a	n/a	Aug 10, 2026	Aug 12, 2026

Common questions

Is the Exelixis, Inc. CEO selling stock?

No. Michael Morrissey reported no open-market sales in the past 12 months.

Why are Exelixis, Inc. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 16% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 84% had no disclosed plan. A trading plan schedules sales in advance.

Are any Exelixis, Inc. insiders buying?

Yes. 1 officer or director reported 1 purchase in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold12 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Dana Aftab EVP, Research and Development	$7.7M 170K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Patrick Haley EVP, Commercial	$7.6M 172K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Julie Smith Director	$4.7M 107K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Jack Wyszomierski Director	$4.6M 103K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Christopher Senner EVP and CFO	$4.6M 100K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Stelios Papadopoulos Director	$4.4M 100K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
George Poste Director	$2.7M 60K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Mary Beckerle Director	$1.9M 42K shares	Not confirmed share of stake is being verified. Why	27% under a disclosed plan 73% no plan disclosed
Bob Oliver Director	$1.3M 30K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Brenda Hefti SVP and General Counsel	$1.2M 25K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Maria Freire Director	$949K 21K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Sue Eckhardt Director	$661K 14K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 17 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Michael Morrissey

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Michael Morrissey are complete.

President and CEO, Director

n/a

Vesting, gifts, unvested awards and holding lines for Michael Morrissey

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Morrissey are complete; balances and unit counts will be added when the check is finished.

−450Kgifted (net of own trusts)

−758Kwithheld by the company for taxes

David Johnson

Director

n/a

Vesting, gifts, unvested awards and holding lines for David Johnson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Johnson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
42,767	$21.69	May 30, 2031	$1.4M
21,464	$42.60	May 28, 2032	$237K
19,133	$50.03	May 26, 2033	$69K

Estimate: options held × ($53.66 − strike price), using the most recent insider trade price on Form 4 (Aug 10, 2026), not a market close.

Stelios Papadopoulos

Director

n/a

−100K

n/a

Vesting, gifts, unvested awards and holding lines for Stelios Papadopoulos

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stelios Papadopoulos are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Christopher Senner

EVP and CFO

n/a

−100K

n/a

Vesting, gifts, unvested awards and holding lines for Christopher Senner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Senner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−117Kwithheld by the company for taxes

Dana Aftab

EVP, Research and Development

n/a

−170K

n/a

Vesting, gifts, unvested awards and holding lines for Dana Aftab

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dana Aftab are complete; balances and unit counts will be added when the check is finished.

−24Kgifted (net of own trusts)

−97Kwithheld by the company for taxes

Jeffrey Hessekiel

EVP & General Counsel

n/a

Vesting, gifts, unvested awards and holding lines for Jeffrey Hessekiel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeffrey Hessekiel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Amy Peterson

EVP Prod Dev & Med Aff & CMO

n/a

Vesting, gifts, unvested awards and holding lines for Amy Peterson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Amy Peterson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
120,000	$21.75	Aug 23, 2030	$3.8M

Estimate: options held × ($53.66 − strike price), using the most recent insider trade price on Form 4 (Aug 10, 2026), not a market close.

Patrick Haley

EVP, Commercial

n/a

−172K

n/a

Vesting, gifts, unvested awards and holding lines for Patrick Haley

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Haley are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−97Kwithheld by the company for taxes

Jack Wyszomierski

Director

n/a

−103K

n/a

Vesting, gifts, unvested awards and holding lines for Jack Wyszomierski

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jack Wyszomierski are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

George Poste

Director

n/a

−60K

n/a

Vesting, gifts, unvested awards and holding lines for George Poste

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for George Poste are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Maria Freire

Director

n/a

−21K

n/a

Vesting, gifts, unvested awards and holding lines for Maria Freire

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Maria Freire are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Brenda Hefti

SVP and General Counsel

n/a

−25K

n/a

Vesting, gifts, unvested awards and holding lines for Brenda Hefti

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Brenda Hefti are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

−12Kwithheld by the company for taxes

Bob Oliver

Director

n/a

−30K

n/a

Vesting, gifts, unvested awards and holding lines for Bob Oliver

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bob Oliver are complete; balances and unit counts will be added when the check is finished.

−1Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,118	$19.28	May 30, 2030	$417K

Estimate: options held × ($53.66 − strike price), using the most recent insider trade price on Form 4 (Aug 10, 2026), not a market close.

Tomas Heyman

Director

n/a

Vesting, gifts, unvested awards and holding lines for Tomas Heyman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tomas Heyman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Mary Beckerle

Director

n/a

−42K

n/a

Vesting, gifts, unvested awards and holding lines for Mary Beckerle

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mary Beckerle are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,854	$23.24	Jan 4, 2031	$391K

Estimate: options held × ($53.66 − strike price), using the most recent insider trade price on Form 4 (Aug 10, 2026), not a market close.

Sue Eckhardt

Director

n/a

−14K

n/a

Vesting, gifts, unvested awards and holding lines for Sue Eckhardt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sue Eckhardt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
23,136	$23.24	Jan 4, 2031	$704K

Estimate: options held × ($53.66 − strike price), using the most recent insider trade price on Form 4 (Aug 10, 2026), not a market close.

Julie Smith

Director

n/a

−107K

n/a

Vesting, gifts, unvested awards and holding lines for Julie Smith

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Julie Smith are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Holdings and share of stake for Exelixis, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$42.2M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $42.2M across 943,605 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $6.9M · 16%

84%

The lighter segment is sales with no plan disclosed in the filing ($35.3M), including tax-related sales outside a plan.

No plan disclosed · $35.3M

Sales with no 10b5-1 plan and no tax reference in the filing. $7.7M of it is Dana Aftab. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Stelios Papadopoulos, Nov 12, 2025

Taxes

1,081,196 shares ($49.5M) were withheld by the company for taxes, which isn't a market sale.

Purchases · 1 buyer (1 trade)

1 officer or director bought shares in this period, in 1 trade(Form 4 code P, leaving out rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust). Across all their filings on record there are 47 purchase trades.

Charitable gifts · 104K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Dana Aftab EVP, Research and Development	170K	$7.7M	0%	18%	Nov 11, 2025 to May 26, 2026
Patrick Haley EVP, Commercial	172K	$7.6M	0%	18%	Nov 20, 2025 to May 20, 2026
Julie Smith Director	107K	$4.7M	0%	11%	Feb 17, 2026 to Feb 18, 2026
Jack Wyszomierski Director	103K	$4.6M	100%	11%	Feb 18, 2026 to Jun 1, 2026
Christopher Senner EVP and CFO	100K	$4.6M	0%	11%	Feb 13, 2026 to May 18, 2026
Stelios Papadopoulos Director	100K	$4.4M	0%	10%	Nov 12, 2025 to Nov 12, 2025
George Poste Director	60K	$2.7M	0%	6%	May 7, 2026 to May 7, 2026
Mary Beckerle Director	42K	$1.9M	27%	5%	Nov 11, 2025 to Aug 10, 2026
Bob Oliver Director	30K	$1.3M	0%	3%	Feb 13, 2026 to Feb 13, 2026
Brenda Hefti SVP and General Counsel	25K	$1.2M	100%	3%	Feb 18, 2026 to May 18, 2026
Maria Freire Director	21K	$949K	0%	2%	May 7, 2026 to May 7, 2026
Sue Eckhardt Director	14K	$661K	100%	2%	Feb 13, 2026 to Jun 1, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$10.5M	$0	$0	$10.5M
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$20.6M	$5.4M	$0	$15.2M
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$9.9M	$333K	$0	$9.6M
Jun 2026	$690K	$690K	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$527K	$527K	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 12 insiders sold; the average is 11 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	944K	12	$42.2M
Oct 16, 2025 1 year earlier	1.08M	14	$43.0M
Oct 16, 2024 2 years earlier	817K	11	$19.8M
Oct 17, 2023 3 years earlier	590K	9	$10.9M
Oct 17, 2022 4 years earlier	534K	8	$10.2M
Oct 17, 2021 5 years earlier	1.51M	14	$33.4M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty17 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Exelixis, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,458 filings on record, 54 filed in the 12-month period, and how we read them

All 1,458 Forms 3, 4 and 5 on record for Exelixis, Inc. (SEC CIK 939767), filed from Nov 22, 2002 to Aug 12, 2026; 54 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages. 28 older filings exist only on paper and could not be read.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (29)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Alan Garber	Mar 25, 2024	35,703 shares, last reported balance as of Mar 21, 2024
Jacqueline Wright	Jun 2, 2023	51,756 shares, last reported balance as of Jun 1, 2023
Vicki Goodman	Apr 5, 2023	307,654 shares, last reported balance as of Apr 3, 2023
Carl Feldbaum	Feb 10, 2023	18,701 shares, last reported balance as of Feb 9, 2023
Peter Lamb	Dec 16, 2022	428,063 shares, last reported balance as of Dec 15, 2022
Lance Willsey	May 27, 2022	424,415 shares, last reported balance as of May 12, 2022
Vincent Marchesi	May 27, 2022	93,989 shares, last reported balance as of May 26, 2022
Charles Cohen	Apr 13, 2022	261,375 shares, last reported balance as of Jul 6, 2021
Gisela Schwab	Jul 28, 2021	703,958 shares, last reported balance as of Jul 26, 2021
George Scangos	May 20, 2020	2,564,936 shares, last reported balance as of May 18, 2020
Deborah Burke	Nov 18, 2014	19,990 shares, last reported balance as of Nov 15, 2014
Pamela Simonton	Feb 18, 2014	28,091 shares, last reported balance as of Feb 15, 2014
Frank Karbe	Feb 18, 2014	109,383 shares, last reported balance as of Feb 15, 2014
Frank McCormick	Dec 9, 2013	No balance on record
Scott Garland	Sep 19, 2013	No balance on record
Lupe Rivera	Aug 17, 2011	22,676 shares, last reported balance as of Aug 15, 2011
Frances Heller	May 17, 2011	17,254 shares, last reported balance as of May 15, 2011
Jeffrey Latts	Dec 12, 2006	No balance on record
Christoph Pereira	Dec 12, 2006	No balance on record
Ian Malcolm	Dec 12, 2006	No balance on record
Jason Fisherman	Sep 9, 2005	7,881 shares, last reported balance as of Sep 8, 2005
Jean Formela	Sep 8, 2005	584,519 shares, last reported balance as of Sep 7, 2005
Gregory Plowman	Dec 15, 2004	No balance on record
Steven James	Dec 12, 2003	No balance on record
Kristine Ball	Dec 12, 2003	4,913 shares, last reported balance as of Nov 12, 2003
Jane Green	Dec 11, 2003	No balance on record
Geoffrey Duyk	Nov 4, 2003	941,355 shares, last reported balance as of Nov 4, 2003
Peter Stalder		No balance on record
Glen Sato		No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Exelixis, Inc. insiders sold $42.2M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Exelixis, Inc. CEO selling stock?

Why are Exelixis, Inc. insiders selling?

Are any Exelixis, Inc. insiders buying?

The evidence

No plan disclosed · $35.3M

Taxes

Purchases · 1 buyer (1 trade)

Charitable gifts · 104K shares

Sales by month